Cyclerion Therapeutics Inc (CYCN NASDAQ) stock market data APIs
$3.2318
0.02(0.6%)
as of May 12, 2025
Try our APIs with
free plan!
Cyclerion Therapeutics Inc Financial Data Overview
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Prev. Close
3.2318
Open
3.2562
High
3.2719
Low
3.051
52 wk Range
1.27-9.4699
Market Cap
10 035 K
Shares Outstanding
3 061 K
Revenue
2 081 K
Beta
1.669
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cyclerion Therapeutics Inc data using free add-ons & libraries
Get Cyclerion Therapeutics Inc Fundamental Data
Cyclerion Therapeutics Inc Fundamental data includes:
- Net Revenue: 2 081 K
- EBITDA: -9 582 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cyclerion Therapeutics Inc News
New
12 Best Biotech Penny Stocks to Invest In
In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past...
The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets
Peter Hecht, the co-founder and CEO of embattled biotech Cyclerion Therapeutics Inc. (Nasdaq: CYCN), is heading up a new startup that's effectively a life raft for Cyclerion's research. Elsewhere in t...
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with...
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
Cyclerion Therapeutics, Inc. – Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Prim...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
